Lyra Therapeutics to present results from ENLIGHTEN 1 Phase 3 study

Lyra Therapeutics (LYRA) announced that the Company plans to present results from the 52-week Extension Stage of the ENLIGHTEN 1 Phase 3 study for LYR-210, the Company’s lead product candidate for CRS, at the annual Combined Otolaryngology Spring Meetings, COSM 2025, being held May 14-18 in New Orleans. The poster will present 52-week results from the Extension Stage of the ENLIGHTEN 1 study in patients with CRS, including the following highlights: LYR-210 was generally well tolerated and no treatment-related serious adverse events reported through Week 52. Repeat LYR-210 treatment demonstrated a favorable safety profile, similar to that observed in the Primary Study Stage in patients with CRS. Durable symptom control through 52 weeks observed after LYR-210 treatment cessation in both non-polyp and polyp patients. In non-polyp patients, despite showing a strong Sham effect in the Primary Study Stage, there was further meaningful improvement in symptoms in crossover patients that subsequently received LYR-210 in the Extension Stage. In the CRS patient subgroup with nasal polyps, crossover Sham-LYR group improved in both symptoms and polyp size consistent with LYR-210 treatment in the Primary Study Stage.